Initiated 2026-09-26 · Price $618.88 (as of 2026-09-25 close, stockanalysis.com) · Mkt cap $17.27bn · Healthcare / contract research (CRO) · Model: verified

Rating: Sell — Conviction: Low

Medpace is the best-run CRO for small biotech sponsors. It has net cash, customers prepay it, and Q2 bookings rose 28%. The price, though, is ~30x EBITDA and ~35x 2026 guided EPS, above the model's bull case. Backlog grew only 4.9% while revenue grew 17%, so revenue growth has to slow. The market is paying for a premium multiple that lasts and a biotech funding boom that continues. Conviction is Low because bookings momentum and the funding upswing are real, and a premium CRO multiple has lasted for years before.

Model value range vs price
Bear $242.17Base $451.70Bull $659.57Price $618.88

Business overview

Medpace runs Phase I–IV clinical trials end to end for biotech and mid-sized pharma sponsors, with its own labs and imaging. Q2 2026 revenue was $707.3mm (+17.2%). About 43% of it ($303.1mm) was reimbursed pass-through costs that carry roughly no margin. Earnings turn on three things: net new awards (a function of biotech funding, cancellations and win rates), the backlog conversion rate (24.1% in Q2, against 21.2% a year earlier), and staff utilization against headcount growing high single digits. Customers pay in advance: current unearned revenue was $854mm at FY2025, which funds working capital and buybacks.

Competition

The large full-service CROs compete for the same work: IQVIA, ICON, Fortrea and Parexel (private). In Q2 2026, IQVIA's R&D Solutions booked at 1.22x book-to-bill, its best since 2022, and said emerging biopharma is 35% of that segment's revenue. ICON booked at 1.51x, but its revenue grew only 1.2%. Medpace's 1.13x book-to-bill was the lowest of the three, though its revenue growth was far higher. The first sign of pressure would be pricing and win rates on small-biotech RFPs as the large CROs chase the funding rebound. On one definition (stockanalysis, 2026-09-25), IQVIA trades at 19.3x EV/EBITDA and 19.8x forward P/E, and Charles River at 19.8x. ICON's 30.4x is inflated by depressed EBITDA; its forward P/E is 15.6x.

Bull case

  1. Biotech funding upswing. Emerging-biopharma funding was ~$35bn in Q2, about double a year earlier (cited on IQVIA's Q2 call). Medpace reports improving RFP flow and more customers with fresh capital. Plays out if net awards keep growing 20%+ and revenue growth holds at low teens into 2028. Model: rev_growth
  2. Margin rises as pass-through falls. Management expects reimbursable costs to fall as a share of revenue in H2 2026, which lifts reported margin. Plays out if EBITDA margin moves from 22.1% toward 24%. Model: ebitda_margin
  3. The premium multiple holds. Stockanalysis's EV/EBITDA has ranged from 20.6x (FY2024) to 34.4x (FY2021), and the premium has lasted through cycles. Plays out if Medpace keeps growing twice as fast as the large CROs. Model: exit_ev_ebitda

Bear case

  1. Conversion reverts, so revenue slows. Backlog is up only 4.9% while revenue is up 17.2%, because conversion is above historical norms (management's words). Plays out if conversion returns toward 21% and FY2027 revenue growth drops to low single digits, leaving a growing headcount underused. Model: rev_growth, ebitda_margin
  2. Customer concentration and cancellations. The top five customers are now 31% of revenue, up from 20%. Small sponsors cancel when funding shuts, and fewer advances would reverse the working-capital tailwind. Plays out if the biotech equity window closes. Model: rev_growth, nwc_pct_rev, wacc
  3. De-rating toward the large CROs. At 30.5x EBITDA on the model's basis, the stock has no cushion if growth normalizes to the ~8–10% the backlog implies. Plays out if the multiple moves toward IQVIA's ~19x. Model: exit_ev_ebitda

Valuation & balance sheet

Metric (definition) Current Own history (range or 5y avg) Peers Source, as-of
EV/EBITDA, aggregator (TTM) 27.7x 20.6x (FY2024) – 34.4x (FY2021), FY-end IQVIA 19.3x · Charles River 19.8x · ICON 30.4x (depressed EBITDA) stockanalysis.com, 2026-09-25
EV/EBITDA, model basis (EV $17.17bn, no leases / FY2025 EBITDA $563.1mm) 30.5x n/a (not restated) n/a (peers not restated) model-inputs.json
EV/FCF (TTM) 23.9x 17.2x (FY2024) – 32.2x (FY2021) IQVIA 26.9x · ICON 15.4x · Charles River 45.4x stockanalysis.com, 2026-09-25
Forward P/E 33.8x 27.3x – 42.2x (FY2021–FY2025) IQVIA 19.8x · ICON 15.6x · Charles River 23.8x stockanalysis.com, 2026-09-25

Model-implied value range (from model-summary.json; generic module, Gordon-growth DCF and exit-EV/EBITDA DCF, midpoints): Bear $242.17 · Base $451.70 · Bull $659.57 per share, i.e. implied returns of −60.9% / −27.0% / +6.6% vs $618.88. These ranges show how the bull and bear drivers translate into value; they are not price targets. The price sits just below the bull case, so the market is already paying for low-teens growth and a lasting premium. The Base-case return is consistent with the Sell.

Re-rating. The exit method assumes a de-rating: 25x against today's 30.5x (−18%), and it gives $565.44. The Gordon method gives $337.97, 40% lower than the exit method. A 10.9% WACC with 4% terminal growth embeds a terminal multiple of roughly half today's (est.), so the Gordon value is a severe de-rating. Even the exit method alone is −9%. The bull exit method (30x) gives $826.82, which is the price's best argument.

Tail, quantified. A harsher case was run outside the committed model, with a cancellation wave: revenue +11%, −5%, 0%, +3%, +3%; EBITDA margin 18%; NWC −24% of revenue (advances shrink); 15x exit; 12.4% WACC; 2.5% terminal growth. That gives $173.63 (−72%).

Balance sheet: net leverage not meaningful (net cash $502.7mm, no funded debt); coverage not meaningful; liquidity $502.7mm cash plus an undrawn revolver (size not verified); no material maturities; ratings n/a (unverified). Buybacks were $917.4mm in FY2025 and $294.7mm in Q2 2026, with $527.0mm of authorization left.

Model note:

Scenario stress test

Reasoned from the bull/bear drivers above. The model column comes from the scenario overlays (Base case + shock).

Scenario Effect Mechanism Magnitude Model Δ value vs Base ($/sh)
S1 Fast equity crash − High-multiple stock de-rates; the biotech funding window shuts briefly Med −$45.91
S2 Slow bear / recession − Biotech funding dries up; cancellations rise; utilization falls. Smaller than Base − Bear ($209.53) on purpose: transitory, while the bear case is a permanent slowdown and de-rating High −$89.96
S3 Rapid rate shock − Higher discount rate on a long-duration multiple; higher rates close the biotech equity window High −$77.86
S4 Slow rate grind − Same channels, grinding Med −$55.74
S5 Soft-landing cuts + Lower rates reopen biotech funding; more small-sponsor trial starts High +$77.74
S6 Recession-driven cuts − Funding stress for small sponsors outweighs the lower discount rate Low −$36.66
S7a Credit liquidity shock − Net cash, so no balance-sheet channel; a brief funding freeze delays awards Low −$31.97
S7b Slow default cycle − Cash-poor small biotechs fail or cancel trials Low −$33.11
S8 Stagflation − Higher discount rate; clinical-staff wage inflation; tighter funding Med −$54.97
S9a Dollar spike + USD-priced contracts with European and Asian staff costs Low +$0.22
S9b Dollar slide − Mirror of S9a Low −$0.22
S10 Melt-up + Biotech IPO window opens; momentum lifts the premium multiple Med +$51.13
S11 Energy supply shock 0 No material effect, not modeled Low $0.00
S12 Mega-cap/AI derating − Premium-multiple growth stocks de-rate in a leadership unwind Low −$28.13

Currently active/on watch per the playbook: state.md lists S3 as partially active, and the macro log records all three legs crossed on 2026-09-24/25 (10Y 5.17%). S8, S10 and S11 are on watch. S3 is a High row here, and S8 and S10 are Med.

Model value change vs Base, by scenario
S2 Slow bear / recession−$89.96S3 Rapid rate shock−$77.86S4 Slow rate grind−$55.74S8 Stagflation−$54.97S1 Fast equity crash−$45.91S6 Recession-driven cuts−$36.66S7b Slow default cycle−$33.11S7a Credit liquidity shock−$31.97S12 Mega-cap/AI derating−$28.13S9b Dollar slide−$0.22S11 Energy supply shock$0.00S9a Dollar spike+$0.22S10 Melt-up+$51.13S5 Soft-landing cuts+$77.74

What would change the call

Upgrades if:

Downgrades (conviction) if:

Watch items

Sources